Which has preferable earnings & valuation, TLX or ANNX?

Telix Pharmaceuticals has higher revenue and earnings than Annexon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A Annexon N/A N/A -$206.69M -$1.16 N/A

Is TLX or ANNX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Annexon N/A -106.15% -79.82%

Does the media prefer TLX or ANNX?

In the previous week, Telix Pharmaceuticals had 8 more articles in the media than Annexon. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 6 mentions for Annexon. Annexon's average media sentiment score of 0.51 beat Telix Pharmaceuticals' score of 0.44 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or DNLI more profitable?

Denali Therapeutics' return on equity of -55.27% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Denali Therapeutics N/A -55.27% -44.24%

Does the media refer more to ANNX or DNLI?

In the previous week, Denali Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 7 mentions for Denali Therapeutics and 6 mentions for Annexon. Denali Therapeutics' average media sentiment score of 1.32 beat Annexon's score of 0.51 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or RCUS more profitable?

Annexon has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Arcus Biosciences' return on equity of -89.54% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Arcus Biosciences -393.16% -89.54% -45.61%

Does the media refer more to ANNX or RCUS?

In the previous week, Annexon and Annexon both had 6 articles in the media. Arcus Biosciences' average media sentiment score of 0.71 beat Annexon's score of 0.51 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANNX or ABCL?

In the previous week, Annexon had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Annexon and 5 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.03 beat Annexon's score of 0.51 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANNX or IOVA?

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Annexon. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 6 mentions for Annexon. Iovance Biotherapeutics' average media sentiment score of 0.58 beat Annexon's score of 0.51 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 1 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Annexon (ANNX) Competitors

$5.07 -0.11 (-2.12%)

As of 08/21/2026 04:00 PM Eastern

Compare

ANNX vs. TLX, DNLI, RCUS, ABCL, and IOVA

Should you buy Annexon stock or one of its competitors? Annexon's main competitors and comparable companies include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Arcus Biosciences (RCUS), AbCellera Biologics (ABCL), and Iovance Biotherapeutics (IOVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annexon compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Telix Pharmaceuticals currently has a consensus price target of $20.40, indicating a potential upside of 80.05%. Annexon has a consensus price target of $15.33, indicating a potential upside of 202.43%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Telix Pharmaceuticals had 8 more articles in the media than Annexon. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 6 mentions for Annexon. Annexon's average media sentiment score of 0.51 beat Telix Pharmaceuticals' score of 0.44 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has higher revenue and earnings than Annexon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Annexon	N/A	-106.15%	-79.82%

Summary

Telix Pharmaceuticals beats Annexon on 7 of the 11 factors compared between the two stocks.

How does Annexon compare to Denali Therapeutics?

Annexon (NASDAQ:ANNX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Annexon has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Annexon presently has a consensus price target of $15.33, suggesting a potential upside of 202.43%. Denali Therapeutics has a consensus price target of $35.92, suggesting a potential upside of 44.13%. Given Annexon's higher possible upside, equities analysts plainly believe Annexon is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Denali Therapeutics' return on equity of -55.27% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Denali Therapeutics	N/A	-55.27%	-44.24%

92.9% of Denali Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Annexon has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A

In the previous week, Denali Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 7 mentions for Denali Therapeutics and 6 mentions for Annexon. Denali Therapeutics' average media sentiment score of 1.32 beat Annexon's score of 0.51 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Annexon compare to Arcus Biosciences?

Annexon (NASDAQ:ANNX) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

92.9% of Arcus Biosciences shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

In the previous week, Annexon and Annexon both had 6 articles in the media. Arcus Biosciences' average media sentiment score of 0.71 beat Annexon's score of 0.51 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon currently has a consensus target price of $15.33, suggesting a potential upside of 202.43%. Arcus Biosciences has a consensus target price of $37.80, suggesting a potential upside of 25.41%. Given Annexon's higher probable upside, equities research analysts clearly believe Annexon is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Annexon has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Arcus Biosciences' return on equity of -89.54% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Annexon has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A

Summary

Annexon and Arcus Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Annexon compare to AbCellera Biologics?

Annexon (NASDAQ:ANNX) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Annexon has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

AbCellera Biologics has higher revenue and earnings than Annexon. AbCellera Biologics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
AbCellera Biologics	$75.13M	46.20	-$146.41M	-$0.54	N/A

In the previous week, Annexon had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Annexon and 5 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.03 beat Annexon's score of 0.51 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Annexon presently has a consensus price target of $15.33, indicating a potential upside of 202.43%. AbCellera Biologics has a consensus price target of $12.83, indicating a potential upside of 13.37%. Given Annexon's higher probable upside, research analysts clearly believe Annexon is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats Annexon on 11 of the 16 factors compared between the two stocks.

How does Annexon compare to Iovance Biotherapeutics?

Annexon (NASDAQ:ANNX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Annexon. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 6 mentions for Annexon. Iovance Biotherapeutics' average media sentiment score of 0.58 beat Annexon's score of 0.51 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	1 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Annexon has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Annexon currently has a consensus target price of $15.33, indicating a potential upside of 202.43%. Iovance Biotherapeutics has a consensus target price of $8.75, indicating a potential upside of 5.55%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Annexon has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Annexon has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Iovance Biotherapeutics	$324.97M	11.56	-$390.98M	-$0.73	N/A

Summary

Iovance Biotherapeutics beats Annexon on 9 of the 15 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$961.17M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-4.37	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	5.17	16.80	13.05	6.20
Net Income	-$206.69M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-4.16%	3.29%	2.09%	0.08%
1 Month Performance	-4.34%	8.23%	6.64%	3.88%
1 Year Performance	119.48%	55.05%	25.02%	16.98%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	2.9278 of 5 stars	$5.07 -2.1%	$15.33 +202.4%	+119.5%	$961.17M	N/A	N/A	60
TLX Telix Pharmaceuticals	3.8668 of 5 stars	$12.42 +2.5%	$20.40 +64.3%	-9.2%	$4.12B	$803.79M	N/A	1,184	Trending News Analyst Forecast Gap Down High Trading Volume
DNLI Denali Therapeutics	3.4026 of 5 stars	$24.95 -2.9%	$35.92 +44.0%	+60.9%	$4.11B	$330.53M	N/A	430	News Coverage Positive News
RCUS Arcus Biosciences	2.998 of 5 stars	$29.61 -2.4%	$37.80 +27.7%	+186.8%	$3.86B	$247M	N/A	500
ABCL AbCellera Biologics	2.307 of 5 stars	$11.57 -3.7%	$12.83 +10.9%	+157.9%	$3.68B	$75.13M	N/A	500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. TLX, DNLI, RCUS, ABCL, and IOVA

How does Annexon compare to Telix Pharmaceuticals?

Summary

How does Annexon compare to Denali Therapeutics?

Summary

How does Annexon compare to Arcus Biosciences?

Summary

How does Annexon compare to AbCellera Biologics?

Summary

How does Annexon compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. TLX, DNLI, RCUS, ABCL, and IOVA

How does Annexon compare to Telix Pharmaceuticals?

Do analysts recommend TLX or ANNX?

Does the media prefer TLX or ANNX?

Which has preferable earnings & valuation, TLX or ANNX?

Which has more risk and volatility, TLX or ANNX?

Is TLX or ANNX more profitable?

Summary

How does Annexon compare to Denali Therapeutics?

Which has more risk and volatility, ANNX or DNLI?

Do analysts rate ANNX or DNLI?

Is ANNX or DNLI more profitable?

Do institutionals and insiders have more ownership in ANNX or DNLI?

Which has higher valuation & earnings, ANNX or DNLI?

Does the media refer more to ANNX or DNLI?

Summary

How does Annexon compare to Arcus Biosciences?

Do insiders and institutionals have more ownership in ANNX or RCUS?

Which has more volatility and risk, ANNX or RCUS?

Does the media refer more to ANNX or RCUS?

Do analysts rate ANNX or RCUS?

Is ANNX or RCUS more profitable?

Which has preferable earnings and valuation, ANNX or RCUS?

Summary

How does Annexon compare to AbCellera Biologics?

Is ANNX or ABCL more profitable?

Which has better earnings and valuation, ANNX or ABCL?

Does the media prefer ANNX or ABCL?

Do institutionals and insiders hold more shares of ANNX or ABCL?

Which has more volatility & risk, ANNX or ABCL?

Do analysts rate ANNX or ABCL?

Summary

How does Annexon compare to Iovance Biotherapeutics?

Does the media prefer ANNX or IOVA?

Do insiders and institutionals hold more shares of ANNX or IOVA?

Which has more volatility and risk, ANNX or IOVA?

Do analysts recommend ANNX or IOVA?

Is ANNX or IOVA more profitable?

Which has higher valuation and earnings, ANNX or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools